Whole-Body Dynamic PET Imaging of Half-Life Extended Variable Domains of Heavy Chain-Only Antibodies: Beyond Blood Pharmacokinetics
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01385 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Etienne Marchal und 15 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Service Hospitalier Frédéric Joliot, 4 Place du…. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Single-Domain Antibodies, Whole Body Imaging, Immunoglobulin Heavy Chains. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Agence Nationale de la Recherche, Sanofi France.
Abstract (Originalsprache)
Nanobody molecules are single-domain antibodies derived from stable and fully functional heavy-chain-only (VHH) camelid antibodies. Due to their small size, approximately 15 kDa, their tissue distribution differs from that of conventional antibodies. This study investigates the whole-body pharmacokinetics (WBPK) and specific binding of half-life extended VHHs (HLE-VHHs) using dynamic whole-body immunoPET imaging in nonhuman primates. A HLE-VHH targeting the IL-6 receptor (CD126-VHH) and its nontargeting control (IRR-VHH) were evaluated in vivo after zirconium-89 radiolabeling. We compared microdoses (0.18 ± 0.11 mg/kg, n = 2) and/or pharmacological doses (coinjection, 3.19 ± 0.02 mg/kg, n = 2) of IRR-VHH, alongside microdoses of CD126-VHH (0.25 ± 0.14 mg/kg, n = 2). Initial dynamic whole-body PET scans (240 min) were followed by static PET scans on days 1, 7, and 14. We validated an image-derived input function against the arterial blood sampling method for kinetic modeling. [89Zr]IRR-VHHs showed predominantly vascular distribution from day 0 to day 14, with comparable activity patterns and tissue distribution between microdose and pharmacological dose administrations. Early [89Zr]CD126-VHH distribution mirrored the nonspecific IRR-VHH pattern, showing strong correlation (R2 = 0.87, slope = 1.1) in uptakes of organs, normalized to blood (standard uptake value ratio, SUVR) values at day 0. Interestingly, by days 7 and 14, [89Zr]CD126-VHH exhibited higher uptake in bone marrow, spleen, liver, and kidneys, suggesting specific binding. The distribution of [89Zr]IRR-VHH in these organs was assumed to reflect the nonspecific uptake of VHHs and was used to estimate the specific binding of [89Zr]CD126-VHH. The specific binding of [89Zr]CD126-VHH was similarly estimated using either the arterial input function or the image-derived input function (R2 = 0.997, p < 0.0001). In plasma, the shorter elimination half-life of [89Zr]CD126-VHH (2.0-1.8 days) compared to microdose [89Zr]IRR-VHH (5.1-5.0 days) or pharmaco-dose [89Zr]IRR-VHH (4.9-4.8 days) suggested target-mediated drug disposition. This study demonstrates the potential of immunoPET for evaluating the target-mediated drug disposition and WBPK of VHH molecules in vivo, providing valuable insights into VHH-based therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris-Saclay, Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Service Hospitalier Frédéric Joliot, 4 Place du Général Leclerc, 91401 Orsay, France.
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-Immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT/UMR-S 1184), 92265 Fontenay-aux-Roses, France.
- Sanofi R&D, Technologiepark 21, 9052 Zwijnaarde, Belgium.
- Sanofi R&D, 13 Quai Jules Guesde, 94400 Vitry sur Seine, France.
ORCID-Profile: Etienne Marchal, Mylène Richard, Bertrand Kuhnast, Tom Van Bogaert, Nicolas Tournier
Förderung
- Agence Nationale de la Recherche
- Sanofi France
Zitieren
APA
Marchal, E., Goutal, S., Richard, M., N'Diaye, E. R., Kuhnast, B., Truillet, C., Chevaleyre, C., Hinnen, F., Lemaitre, J., Relouzat, F., Van Bogaert, T., Casteels, P., De Brabandere, V., Jouannot, E., Besson, F. L., & Tournier, N. (2026). Whole-Body Dynamic PET Imaging of Half-Life Extended Variable Domains of Heavy Chain-Only Antibodies: Beyond Blood Pharmacokinetics. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01385
Vancouver
Marchal E, Goutal S, Richard M, N'Diaye ER, Kuhnast B, Truillet C, et al. Whole-Body Dynamic PET Imaging of Half-Life Extended Variable Domains of Heavy Chain-Only Antibodies: Beyond Blood Pharmacokinetics. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01385
BibTeX
@article{Marchal2026,
author = {Marchal, Etienne and Goutal, Sébastien and Richard, Mylène and N'Diaye, Elisa-Racky and Kuhnast, Bertrand and Truillet, Charles and Chevaleyre, Céline and Hinnen, Françoise and Lemaitre, Julien and Relouzat, Francis and Van Bogaert, Tom and Casteels, Peter and De Brabandere, Veronique and Jouannot, Erwan and Besson, Florent L and Tournier, Nicolas},
title = {Whole-Body Dynamic PET Imaging of Half-Life Extended Variable Domains of Heavy Chain-Only Antibodies: Beyond Blood Pharmacokinetics},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01385}
}
EUVIMED